Home Tell a Colleague Print Page
Email

*Required fields

*From (your name)
*Your e-mail address
*Your colleague's e-mail address

The following e-mail will be sent:

Hi. I thought you'd be interested in learning about the new Hib vaccine HIBERIX® [Haemophilus b Conjugate Vaccine (Tetanus Toxoid Conjugate)].

Just click on this link (or copy and paste the link into your browser).
http://www.hiberix.com

Indication

HIBERIX is indicated for active immunization as a booster dose for the prevention of invasive disease caused by Haemophilus influenzae type b (Hib). HIBERIX is approved for use in children 15 months through 4 years of age (prior to fifth birthday).

Important Safety Information

  • In clinical studies, adverse events in children receiving HIBERIX included pain and redness at the injection site, fever, fussiness, loss of appetite, and restlessness
  • A severe allergic reaction (eg, anaphylaxis) after a previous dose of any Hib or tetanus toxoid-containing vaccine or any component of HIBERIX is a contraindication
  • If Guillain-Barré syndrome has occurred within 6 weeks of receipt of a prior vaccine containing tetanus toxoid, the decision to give HIBERIX should be based on potential benefits and risks
  • Vaccination with HIBERIX may not protect 100% of susceptible individuals

*This information is used only for the purpose of sending this e-mail.



*Enter the text as you see it

Order HIBERIX at gskvaccinesdirect.com - Get Started
Learn more about the immunogenicity of HIBERIX - Click here
Learn more about the safety of HIBERIX - Click here

Indication

HIBERIX is indicated for active immunization as a booster dose for the prevention of invasive disease caused by Haemophilus influenzae type b (Hib). HIBERIX is approved for use in children 15 months through 4 years of age (prior to fifth birthday).

Important Safety Information

  • In clinical studies, adverse events in children receiving HIBERIX included pain and redness at the injection site, fever, fussiness, loss of appetite, and restlessness
  • A severe allergic reaction (eg, anaphylaxis) after a previous dose of any Hib or tetanus toxoid-containing vaccine or any component of HIBERIX is a contraindication
  • If Guillain-Barré syndrome has occurred within 6 weeks of receipt of a prior vaccine containing tetanus toxoid, the decision to give HIBERIX should be based on potential benefits and risks
  • Vaccination with HIBERIX may not protect 100% of susceptible individuals

Download Complete Prescribing Information for HIBERIX